Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.40 |
| ▸ | ACACB | O00763 | 11/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
| ▸ | LIPC | P11150 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19937830 | 0.88 | RBP4 (0.44) | RBP4 | |
| SCHEMBL19937832 | 0.88 | RBP4 (0.44) | RBP4 | |
| SCHEMBL19937836 | 0.70 | RBP4 (0.48) | RBP4 | |
| SCHEMBL21668750 | 0.70 | NOTUM (0.54) | PDE10A | |
| SCHEMBL7949976 | 0.69 | CARM1 (0.37) | — | |
| SCHEMBL19937839 | 0.69 | RBP4 (0.50) | RBP4 | |
| SCHEMBL19937835 | 0.69 | RBP4 (0.47) | RBP4 | |
| SCHEMBL19937833 | 0.69 | RBP4 (0.47) | RBP4 | |
| SCHEMBL19937840 | 0.69 | RBP4 (0.50) | RBP4 | |
| SCHEMBL21654087 | 0.68 | LIPG (0.42) | LIPGACACBPDE3BPDE3APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | LIPG 1725/4885ACACB 2215/4885PDE3B 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.